Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01846208 · ClinicalTrials.gov registry record · Phase 2
Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy
A Phase 2 study of Food Allergy, sponsored by Hugh A Sampson, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 5
- Study locations
NCT01846208 is a Phase 2 study of Food Allergy that has completed, run by Hugh A Sampson, MD. The registered enrollment target is 92 participants, below the 959-participant average among 17 other Food Allergy trials with a reported enrollment target (90% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT01846208, a Phase 2 study of Food Allergy, has completed, sponsored by Hugh A Sampson, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to compare Baked Egg vs. Egg Oral Immunotherapy for inducing sustained unresponsiveness to egg exposure in children.
Conditions Studied
Interventions
- DRUG Egg Oral Immunotherapy
- DRUG Baked Egg
Study Locations (5)
Arkansas
- Arkansas Children's Hospital - Little Rock
Colorado
- National Jewish Health - Denver
Maryland
- Johns Hopkins University - Baltimore
New York
- Icahn School of Medicine at Mount Sinai - New York
North Carolina
- University of North Carolina - Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2013-07 |
| Est. Completion | 2018-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01846208
The ClinicalTrials.gov registry entry for NCT01846208 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 959-participant average among 17 other Food Allergy trials with a reported enrollment target (90% lower). The listed sponsor is Hugh A Sampson, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Food Allergy appearing as the primary indexed condition, and to 2 interventions - of which Egg Oral Immunotherapy is the first listed.
NCT01846208 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Arkansas, Colorado, Maryland.
Frequently Asked Questions
What is clinical trial NCT01846208 about?
NCT01846208 is a clinical study titled "Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy". The purpose of this study is to compare Baked Egg vs. Egg Oral Immunotherapy for inducing sustained unresponsiveness to egg exposure in children.
What is the current status of trial NCT01846208?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2013-07. Estimated completion is 2018-09-30.
What conditions does trial NCT01846208 study?
This clinical trial studies the following conditions: Food Allergy.
What interventions are being tested in trial NCT01846208?
The interventions under investigation include: Egg Oral Immunotherapy (DRUG), Baked Egg (DRUG).
Who is sponsoring clinical trial NCT01846208?
This trial is sponsored by Hugh A Sampson, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01846208 being conducted?
This trial has 5 study locations across Arkansas, Colorado, Maryland, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Food Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
RECRUITING · Phase 2
-
Omalizumab Weight-Based Dosing Efficacy Trial
RECRUITING · Phase 2
-
Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy
COMPLETED · Phase 2
-
Multi Immunotherapy to Test Tolerance and Xolair
COMPLETED · Phase 2
-
Preventing Anaphylaxis With Acalabrutinib
COMPLETED · Phase 2
-
Effect of Omalizumab in the Skin of Food Allergy Patients
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.